2 citations
,
March 2023 in “Frontiers in medicine” This case report presents the first successful treatment of perifolliculitis capitis abscedens et suffodiens using a regimen of adalimumab and baricitinib, resulting in almost complete healing after nine months.
February 2024 in “PloS one” This review concluded that oral tofacitinib and adalimumab are promising treatments for cicatricial alopecia, showing effectiveness in improving signs and symptoms but requiring regular monitoring for adverse effects. The authors emphasize the need for further extensive studies to solidify these findings.
1 citations
,
September 2023 in “Rheumatology advances in practice” This case report describes a 42-year-old woman with rheumatoid arthritis who developed extensive impetiginized pityriasis amiantacea potentially linked to her anti-TNF-α therapy with golimumab. Discontinuing the drug and other treatments led to significant clinical improvement within a month.
1 citations
,
April 2012 in “Informa Healthcare eBooks” Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.
May 2025 in “Orphanet Journal of Rare Diseases” This review suggests that immunomodulators, including TNF-α blockers and IL inhibitors, may improve symptoms of moderate-to-severe dissecting cellulitis of the scalp, but their effects on hair regrowth and scarring remain unclear.